Publicação: Crystal Structure Determination of Mebendazole Form A Using High-Resolution Synchrotron X-Ray Powder Diffraction Data
Carregando...
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
John Wiley & Sons Inc
Tipo
Artigo
Direito de acesso
Acesso restrito
Resumo
The crystal structure determination of mebendazole form A, an anthelmintic drug, was performed for the first time by applying the DASH software program to synchrotron X-ray powder diffraction data, and supported by a satisfying Rietveld fit. This polymorph of mebendazole crystallizes in a triclinic (P (1) over bar) space group, with unit-cell parameters a = 5.5044(2)angstrom, b = 11.2872(2)angstrom, c = 12.5276(5)angstrom, a= 66.694(2)degrees, beta = 82.959(2)degrees, gamma = 78.443(2)degrees, V = 699.52(5)angstrom(3), Z = 2, M = 295.293 g mol(-1), rho(calc) = 1.4021 g cm(-3), and rho(meas) = 1.3935(66) g cm(-3), which were obtained by means of the unit-cell formula weight and a picnometric measurement, respectively. The goodness-of-fit and R-factors were, respectively: chi(2) = 1.746, R(F)(2) = 1.69%, R(wp) = 5.72%, and R(p) = 4.37%. A weak nonclassical hydrogen bond involving the atoms N(3)-H(23)center dot center dot center dot O(11) may be responsible for the greater stability of the polymorphic form A of mebendazole due to the strongest electronegativity of nitrogen. (C) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:1734-1744, 2010
Descrição
Palavras-chave
X-ray powder diffractometry, crystal structure, polymorphism, crystallography, ab initio calculations, quantitative phase analysis, synchrotron, mebendazole, polymorph A, anthelmintic drug
Idioma
Inglês
Como citar
Journal of Pharmaceutical Sciences. Hoboken: John Wiley & Sons Inc, v. 99, n. 4, p. 1734-1744, 2010.
